<DOC>
	<DOCNO>NCT00556998</DOCNO>
	<brief_summary>This study design collect additional pharmacokinetic safety data voriconazole immunocompromised adolescent receive intravenous oral voriconazole . This help establish voriconazole dose recommendation adolescent .</brief_summary>
	<brief_title>A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Subjects expect develop neutropenia follow chemotherapy . Subjects require treatment prevention systemic fungal infection . Subjects history severe intolerance azole antifungal agent . Subjects document bacterial viral infection time study entry respond appropriate treatment infection .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>pharmacokinetics safety data voriconazole immunocompromised adolescent</keyword>
</DOC>